Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan

被引：0
作者：
Hiroki Nagai
Shiro Tanaka
Miyuki Niimi
Nanae Seo
Takahiko Sasaki
Hiroshi Date
Michiaki Mishima
Hiroyasu Yasuda
Kazuhiro Yanagihara
机构：
[1] Outpatient Oncology Unit,Department of Respiratory Medicine, Graduate School of Medicine
[2] Kyoto University Hospital,Department of Clinical Trial Design and Management, Translational Research Center
[3] Kyoto University,Department of Respiratory Medicine
[4] Kyoto University Hospital,Department of Thoracic Surgery, Graduate School of Medicine
[5] Tohoku University School of Medicine,Department of Clinical Application
[6] Kyoto University,Department of Translational Clinical Oncology, Graduate School of Medicine
[7] Tohoku University Translational Research Center,undefined
[8] Kyoto University,undefined
来源：
International Journal of Clinical Oncology | 2011年 / 16卷
关键词：
Erlotinib; Epidermal growth factor receptor; Epidermal growth factor receptor–tyrosine kinase inhibitor; Adverse events; Non-small-cell lung cancer; Japanese outpatients;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] PHASE II TRIAL OF ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Okano, Yoshio
    Shinohara, Tsutomu
    Machida, Hisanori
    Hatakeyama, Nobuo
    Takeuchi, Eiji
    Doi, Hiroyuki
    Kubota, Tetsuya
    Yokoyama, Akihito
    Ogushi, Fumitaka
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1175 - S1176
  • [12] Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer
    Zhou, Songwen
    Ren, Shengxiang
    Yan, Lianghua
    Zhang, Ling
    Tang, Liang
    Zhang, Jie
    Zhou, Caicun
    RESPIROLOGY, 2009, 14 (05) : 709 - 715
  • [13] Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer
    Shibata, Yuji
    Murakami, Shuji
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (06) : 653 - 659
  • [14] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
  • [15] Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer
    Hotta, Katsuyuki
    Kiura, Katsuyuki
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (07) : 991 - 997
  • [16] Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
    Melosky, B.
    Agulnik, J.
    Assi, H.
    CURRENT ONCOLOGY, 2008, 15 (06) : 279 - 285
  • [17] The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer
    Boussageon, Maxime
    Swalduz, Aurelie
    Perol, Maurice
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (10) : 1071 - 1080
  • [18] Erlotinib in the treatment of non-small cell lung cancer
    Brown, Ewan R.
    Shepherd, Frances A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (05) : 767 - 775
  • [19] Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
    Zhou, Zheng-Tao
    Xu, Xin-Hua
    Wei, Qing
    Lu, Ming-qian
    Wang, Jie
    Wen, Cai-Hong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1123 - 1127
  • [20] Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
    Zheng-Tao Zhou
    Xin-Hua Xu
    Qing Wei
    Ming-qian Lu
    Jie Wang
    Cai-Hong Wen
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 1123 - 1127
12345